

EUROPEAN FORUM FOR RESEARCH AND EDUCATION IN ALLERGY AND AIRWAY DISEASES


New tools in respiratory care added value of digital health

Sven Seys, PhD EUFOREA – KU Leuven Belgium



www.euforea.eu


Digital health tools: eHealth versus mHealth





Chronic upper airway diseases affect a significant portion of the population

Need for better disease control of patients with CRDs






40% of CRS patients are UNCONTROLLED

despite maximal medical therapy and sinus surgery


	Total (<i>n</i> = 389)	CRSsNP (<i>n</i> = 177, 45.5%)	CRSwNP (<i>n</i> = 212, 54.5%)	<i>P</i> -value
Age (mean ± SD)	47.3 ± 14.1	45.7 ± 15.0	49.3 ± 12.7	
Gender (% male)	53.2	42.5	66.1	<0.0001
Atopy (%)	33.4	28.8	39.0	0.034
Aspirin intolerance (%)	4.1	0.0	9.0	<0.0001
Asthma (%)	17.7	12.3	24.3	0.002
Smoking (%)	15.4	17.9	12.4	0.135
Revision FESS (%)	29.0	23.6	35.6	0.009



Up to 35% of AR patients are UNCONTROLLED


despite conventional pharmacotherapy

	ΙΤ	Non-IT
Number of patients (n)	82	352
Men (%)	34 (41.5)	151 (42.9)
Women (%)	48 (58.5)	201 (57.1)
Mean age (year, mean, standard deviation)	33.1 (11.6)	34.6 (12.7)
Atopy		
Mono-sensitized (%)	10 (12)	104 (30)
Poly-sensitized (%)	72 (88)	248 (70)
Asthma (%)	12 (14)	42 (12)
Pharmacological treatment (n)	26 (32)	215 (61)
Anti-histaminicum (%)	10 (12)	72(20)
Intranasal corticosteroids (ICS)(%)	4 (5)	56 (16)
Anti-histaminicum + ICS (%)	12 (15)	87 (25)






4 Key Barriers / Solutions throughout the holistic care continuum Efficiency and Multidisciplinary Collaboration




Mapping mHealth tools in CRD





Sleurs K, Seys SF, Allergy 2019


Mapping mHealth tools in CRD






Sleurs K, Seys SF, Allergy 2019

Mapping mHealth tools in CRD








ISBN: 978-0-12-813471-9

Patient reported outcome measures

mySinusitisCoach

- **Sinusitis Diary**
- Registration medication use
- Weekly reminder
- **Patient feedback**





-

18

Show


17

Results

15

16






Seys et al., Rhinology, 2018







How much are your nose symptoms bothering you today?

How much are your eye symptoms bothering you today?

How much are your asthma symptoms bothering you today?

Bousquet et al., Allergy, 2015



Allergy Diary

MACVIA*LR

0

Physiological parameters

- Evaluation lung function by daily peak flow measurements (PEF)
- Evaluation nasal patency by peak nasal flow measurements?
- Evaluation of general health-related parameters by wireless tracking devices
 - Pulse rate
 - Physical activity
 - Sleep quality





asthma

COPD

rhinitis CRS

asthma

COPD CRS

Reminders for taking medication


Patient reported medication use via mHealth tool



Smart sensors

- Inhalers
- Nasal sprays
- > Blisters







Endotype-driven treatment

- Blood/nasal secretion/sputum eosinophils
- FeNO, nNO, VOCs in exhaled breath
- Need for point of care solutions
- Results integrated in mHealth tool



myAirCoach

Weekly

X-halo (EBT)

Planned: Fri, 13/01/2017			
Link	Date		
ACQ week	🗹 Tue, 17/01/2017		
Piko-1 (FEV1)	🗹 Tue, 17/01/2017		
NIOX Vero (FeNO)	🗹 Tue, 17/01/2017		

Tue, 17/01/2017







Based on geo-localization

need for specific consent of patient

Estimated individual exposure

- Outdoor air pollution
- Indoor air pollution
- Pollen counts

Alerts might lead to individual patient actions

- > Modify activity
- Personal protection
- Medication



Environmental exposure

Added value of mHealth tools for different stakeholders

PHYSICIAN

- Early identification of uncontrolled disease and resistance to therapy
- Standardized follow-up after medical treatment and surgery

HEATLH CARE SYSTEM

- Cost saving thanks to reducing unnecessary consultations and hospitalizations
- Increasing time efficiency by better patient education

PATIENT

- **Tracking** of symptoms and objective monitoring of disease parameters
- Personalized feedback on disease progression and control
- Sharing detailed reports with physician
- Better education about disease, treatment options and correct use of drugs or devices

RESEARCHER

• Generation of **real-life data**, comparing efficacy of treatment strategies

SOCIETY

- Reduced absenteeism and presenteeism at work
- Reduction of economic costs
- Disease prevention by timely treatment



Adding value for all stakeholders


requires adoption of mHealth tool in clinical practice

STEP 1	One application for multiple CRDs CHRONIC RHINOSINUSITIS – ALLERGIC RHINITIS – ASTHMA
STEP 2	Adding value for patient and physician PERSONALISED PATIENT FEEDBACK and IMPROVED PHYSICIAN DASHBOARD
STEP 3	Geographical coverage - standardisation 13 EU COUNTRIES (phased implementation in 2019)
STEP 4	Adoption in clinical practice to support patient and physician throughout the care pathway



Adding value for all stakeholders

requires adoption of mHealth in clinical practice







PATIENT REGISTERS IN THE APP VIA 2 ENTRIES

1/ Non Diagnosed by Self Assessment – 2/ Diagnosed and in Treatment

BENEFITS

WHY

Non Diagnosed

- Reach General Population
- Improve Detection
- Improve Diagnosis and Referral

STEP


1

Diagnosed

Monitor Diagnosed Patients

WHAT

- Self Assessment for Non Diagnosed Patients
- Registration of Profile







2

PATIENT STARTS MONITORING AND KEEPS A DIARY IN THE APP


BENEFITS

WHY

- Standardized follow up of patient outcomes
- Evaluate outcomes after new treatment

WHAT

- Health Diary to monitor airway symptoms (VAS)
- > Additional validated questionnaires available
- > Feedback to the patient





PATIENT CONSULTS THE PHYSICIAN EVALUATE DISEASE STATUS and PRESCRIBE TREATMENT

PATIENT INDIVIDUAL FILE

STEP


3

WHY

- Continuous monitoring of symptoms
- > Feedback on disease control
- > Feedback on adherence to medication
- Prediction of outcomes after surgery

WHAT

- Remote access to patient results
- Create patient groups (severe, surgery, for biological treatment)
- Access from KWS (in progress)





www.euforea.eu

Want to now more about EUFOREA?

Follow us on Twitter – Facebook - Website





Debate on the positioning of Dymista, a nasal treatment for Allergic Rhinitis. Dymista is a symptomatic treatment containing an...